BAJAJ BROKING
Panacea Biotec won a $14.95M (Rs 1.27B) UNICEF contract to deliver 115M doses of bOPV in 2025. This award aligns with their role in global polio eradication, supporting health initiatives worldwide.
Panacea Biotec has secured a $14.95 million (approximately Rs 1.27 billion) award from UNICEF for the supply of 115 million doses of bivalent Oral Polio Vaccine (bOPV) in 2025. This development underscores the company's contribution to global healthcare initiatives, particularly in polio eradication efforts. The contract further solidifies Panacea Biotec’s reputation as a reliable vaccine supplier on the international stage.
Also read: Deep Ind Announces Board Meeting to Discuss QIP-Based Fundraising on 28 Dec
Contract Value: $14.95 million (Rs 1.27 billion).
Scope: Supply of 115 million doses of bOPV.
Timeline: Delivery in 2025.
Significance: Supports UNICEF’s global polio eradication programme.
Also read: Apollo Healthco to Acquire Searchlight Health Software Unit for ₹67
The $14.95 million agreement involves supplying bOPV doses to various countries in need of polio vaccines. Panacea Biotec, a leading pharmaceutical and biotechnology company, has consistently partnered with global health organisations to deliver quality vaccines. This contract is a testament to their production capabilities and strategic focus on addressing public health challenges.
Details | Specifications |
Organisation | UNICEF |
Vaccine Type | bivalent Oral Polio Vaccine |
Total Doses | 115 million |
Contract Value | $14.95 million (Rs 1.27B) |
Delivery Year | 2025 |
Winning this UNICEF contract enhances Panacea Biotec’s position as a key player in the global pharmaceutical market. This milestone is expected to have a positive impact on the company’s revenue and operational capacity. Investors may closely monitor the Panacea Biotec share price, given the potential growth opportunities arising from such high-value contracts.
Panacea Biotec’s $14.95 million award from UNICEF for bOPV supply highlights the company's vital role in global health initiatives. This development not only reinforces their reputation but may also influence the Panacea Biotec share price positively as they expand their international footprint.
Also read: Biocon Achieves VAI Status for Bengaluru Facility After US FDA Inspection
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading